Navigation Links
Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
Date:1/7/2014

TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency (EMA). In Europe, Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrence of symptomatic venous thromboembolism (VTE). If approved, edoxaban will be authorized for marketing in all European member states.

The MAA submission is based on data from an extensive global clinical trial program that compared treatment with once-daily edoxaban to warfarin, a current standard of care for patients with atrial fibrillation (AF) or VTE. The two clinical trials that formed the basis of the submission, ENGAGE AF-TIMI 48 and Hokusai-VTE, are the largest comparative trials of a novel oral anticoagulant in these patient populations, involving 21,105 and 8,292 patients, respectively.1,2

"The submission of our MAA in Europe for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including AF or VTE," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of Research and Development, Daiichi Sankyo Co., Ltd. and President and CEO of Daiichi Sankyo, Inc. in the United States. "This milestone brings us one step closer to providing a new treatment option to patients living with AF or VTE, and we look forward to working with the EMA as it conducts its review of edoxaban."

Edoxaban is currently
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
2. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
3. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
4. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
5. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
6. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
7. Orexigen Resubmits Contrave New Drug Application
8. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
9. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
10. Omeros Submits New Drug Application to U.S. FDA for OMS302
11. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CHICAGO , Aug. 27, 2015  Hill-Rom Holdings, ... to a management presentation at the Morgan Stanley Global ... ET. You are invited to listen to ... http://ir.hill-rom.com/events.cfm  or access it directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . ... be available one hour after the conclusion of the ...
(Date:8/27/2015)... pharmaceutical and medical device companies and leading law firms will ... on Oct. 20, discussing issues surrounding regulatory compliance, ... Litigation Conferences has announced. To learn more ... The program is co-chaired by Megan Grossman ... Hart Yeary of Dechert LLP. Topics include: ...
(Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
Breaking Medicine Technology:Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... 20, 2011 Comprehensive Care Corporation (OTC BB: CHCR), ... management services for managed care companies throughout the U.S., ... has been praised by the Chamber of Commerce of ... Leadership Advisory Council in "helping to shape and drive ...
... YDNT ) today announced record earnings per share for ... ended September 30, 2011. Sales for the third quarter ... $26.4 million reported for the third quarter of 2010. Income from ... $6.1 million in the prior year quarter. Net income for the ...
Cached Medicine Technology:Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 3Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 4Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 5
(Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon ... The new facility will be located at US Highway 19 North and Highlands Boulevard, less ... 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... Collegedale, Tennessee (PRWEB) , ... August 27, 2015 , ... ... preservatives or high fructose corn syrup, is changing the expectation of how protein bars ... a rich, indulgent taste unlike any other protein bar on the market today. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... from having problems paying medical bills, and having bill problems ... medicines, a new study has found. According to a ... Journal of Public Health , after taking age, income and ... the odds of accruing debt related to medical care or ...
... Alan Mozes HealthDay Reporter , THURSDAY, June 16 ... habits of America,s teens, new data from the U.S. Centers ... Not only are high school kids guzzling far too ... CDC research team found. In fact, just one in ...
... pilot study of etanercept for treatment of dermatomyositis found ... the drug were successfully weaned from steroid therapy. These ... further investigate the safety and efficacy of etanercept. Results ... of Neurology , a journal published by Wiley-Blackwell on ...
... new study published today in the journal Child ... a poor "gut sense" of numbers can lead to ... math proficiency. This inaccurate number sense is just one ... led by Dr. Michele Mazzocco of the Kennedy Krieger ...
... UT Southwestern Medical Center scientists are shedding new ... fast-acting antidepressant response in patients with treatment-resistant depression. ... as a fast-acting antidepressant potentially has use in emergency ... very sharp increase that immediately relieves depression," said Dr. ...
... of death across a population has evolved in recent ... heart attack and cancer, the role of behavioral factorsincluding ... the 1990s. More recent research has begun to ... mortality. In the first comprehensive analysis of such studies, ...
Cached Medicine News:Health News:Medical debt occurs despite insurance, UA study shows 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 3Health News:Etanercept shows promise for treating dermatomyositis 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: